Business Wire

OR-LATTICE-SEMICONDUCTOR

5.12.2023 18:21:34 CET | Business Wire | Press release

Share
Lattice Continues Rapid Product Portfolio Expansion Enabling the Next Era of Innovation

Today at the Lattice Developers Conference, Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, continued its rapid product portfolio expansion with the launch of multiple new hardware and software solutions. Lattice introduced two new innovative mid-range FPGA device families built on the award-winning mid-range Lattice Avant™ platform – Lattice Avant™-G and Lattice Avant™-X, designed for general purpose and advanced connectivity, respectively. Lattice announced new versions of its application-specific solution stacks for artificial intelligence (AI), embedded vision, security, and factory automation, each of which are expanded with new features and capabilities to help accelerate customer time-to-market. Lattice released updated versions of its software tools and Glance by Mirametrix® computer vision software.

“At Lattice, we’re focused on enabling our customers to accelerate their designs with new levels of power efficiency and performance through our rapidly growing hardware and software portfolio,” said Esam Elashmawi, Chief Strategy and Marketing Officer, Lattice Semiconductor. “We’re excited to expand on the strong customer and developer momentum we’ve established for Lattice Avant, enabling the next era of innovation.”

Innovative Mid-range FPGAs

Built on the award-winning Lattice Avant platform, the Avant-G and Avant-X FPGA families offer power efficiency, advanced connectivity, and optimized compute for mid-range applications across the Communications, Computing, Industrial, and Automotive markets.

Lattice Avant™-G FPGA Family
Avant-G general purpose FPGAs are designed to enable a wide range customer needs by offering seamless, flexible interface bridging and optimized compute for system expandability. Lattice Avant-G devices offer best-in-class signal processing and AI, flexible I/O supporting a range of system interfaces, while providing dedicated LPDDR4 memory interfaces at 2400 Mbps.

Lattice Avant™-X FPGA Family
Avant-X advanced connectivity FPGAs are designed to enable high bandwidth and security, with a feature set tailored to customer needs for signal aggregation and high throughput. Lattice Avant-X devices offer up to 1 Terabit per second total system bandwidth, PCIe® Gen 4 controllers with hard DMA, and a security engine to encrypt user data in motion providing quantum safe cryptography.

Lattice Avant-G and Avant-X FPGAs are sampling today and are supported by the latest releases of Lattice Propel™ and Lattice Radiant™ design software.

Expanded Solution Stacks

Lattice’s solution stacks are designed to speed customer development and time-to-market by giving them a toolkit of hardware, software, and IP tailored to the needs of their application. Lattice today announced four solution stack updates in AI with Lattice sensAI™, embedded vision with Lattice mVision™, security with Lattice Sentry™, and factory automation with Lattice Automate™. These updates include improved performance with upgraded an accelerator engine, expanded IP and reference designs, added security features, and enablement of more industry standards.

Enhanced Software Capabilities

Lattice is committed to providing best-in-class, easy-to-use software tools that help enhance customers’ design experience and design environment. Key updates to Lattice Propel™ and Lattice Radiant™ software includes adding full support for the new Lattice Avant-G and Avant-X FPGA families, the introduction of enhanced ease-of-use and scripting to Radiant, and expanding the IP portfolio in Propel.

Advanced computer vision software Glance by Mirametrix® was also updated with new features to expand its applicability across Edge applications for various markets. Updates include a new smart avatar privacy feature and 3D head pose for low power capability.

These product announcements were made today during the livecast at the Lattice Developers Conference, a replay of which will soon be available on the event portal site. Lattice Developers Conference is taking place virtually Dec. 5-7, 2023, featuring an incredible lineup of keynotes, breakout sessions, and a robust showcase of FPGA-based technology demonstrations from Lattice and other industry leaders.

For more information on the new products, please read the latest blog and visit:

About Lattice Semiconductor

Lattice Semiconductor (NASDAQ: LSCC) is the low power programmable leader. We solve customer problems across the network, from the Edge to the Cloud, in the growing Communications, Computing, Industrial, Automotive, and Consumer markets. Our technology, long-standing relationships, and commitment to world-class support let our customers quickly and easily unleash their innovation to create a smart, secure, and connected world.

For more information about Lattice, please visit www.latticesemi.com. You can also follow us via LinkedIn, Twitter, Facebook, YouTube, WeChat, or Weibo.

Lattice Semiconductor Corporation, Lattice Semiconductor (& design), and specific product designations are either registered trademarks or trademarks of Lattice Semiconductor Corporation or its subsidiaries in the United States and/or other countries. The use of the word “partner” does not imply a legal partnership between Lattice and any other entity.

GENERAL NOTICE: Other product names used in this publication are for identification purposes only and may be trademarks of their respective holders.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231205062926/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release

FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease

Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release

Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border

Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release

In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo

Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release

Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d

Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release

IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye